Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine.
Clofazimine
NTM
Pharmacology
Side effects
Therapy
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
08 Feb 2024
08 Feb 2024
Historique:
received:
30
10
2023
accepted:
12
01
2024
medline:
8
2
2024
pubmed:
8
2
2024
entrez:
8
2
2024
Statut:
aheadofprint
Résumé
Non-tuberculous mycobacteria (NTM) are generally free-living organism, widely distributed in the environment, with sporadic potential to infect. In recent years, there has been a significant increase in the global incidence of NTM-related disease, spanning across all continents and an increased mortality after the diagnosis has been reported. The decisions on whether to treat or not and which drugs to use are complex and require a multidisciplinary approach as well as patients' involvement in the decision process. This review aims at describing the drugs used for treating NTM-associated diseases emphasizing the efficacy, tolerability, optimization strategies as well as possible drugs that might be used in case of intolerance or resistance. We also reviewed data on newer compounds highlighting the lack of randomised clinical trials for many drugs but also encouraging preliminary data for others. We also focused on non-pharmacological interventions that need to be adopted during care of individuals with NTM-associated diseases CONCLUSIONS: Despite insufficient efficacy and poor tolerability this review emphasizes the improvement in patients' care and the needs for future studies in the field of anti-NTM treatments.
Sections du résumé
BACKGROUND
BACKGROUND
Non-tuberculous mycobacteria (NTM) are generally free-living organism, widely distributed in the environment, with sporadic potential to infect. In recent years, there has been a significant increase in the global incidence of NTM-related disease, spanning across all continents and an increased mortality after the diagnosis has been reported. The decisions on whether to treat or not and which drugs to use are complex and require a multidisciplinary approach as well as patients' involvement in the decision process.
METHODS AND RESULTS
RESULTS
This review aims at describing the drugs used for treating NTM-associated diseases emphasizing the efficacy, tolerability, optimization strategies as well as possible drugs that might be used in case of intolerance or resistance. We also reviewed data on newer compounds highlighting the lack of randomised clinical trials for many drugs but also encouraging preliminary data for others. We also focused on non-pharmacological interventions that need to be adopted during care of individuals with NTM-associated diseases CONCLUSIONS: Despite insufficient efficacy and poor tolerability this review emphasizes the improvement in patients' care and the needs for future studies in the field of anti-NTM treatments.
Identifiants
pubmed: 38329686
doi: 10.1007/s15010-024-02183-3
pii: 10.1007/s15010-024-02183-3
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Porvaznik I, Solovič I, Mokrý J. Non-tuberculous mycobacteria: classification, diagnostics, and therapy. Adv Exp Med Biol. 2017;944:19–25.
pubmed: 27826888
doi: 10.1007/5584_2016_45
Kim C-J, Kim N-H, Song K-H, Choe PG, Kim ES, Park SW, Kim H-B, Kim N-J, Kim E-C, Park WB, Oh M. Differentiating rapid- and slow-growing mycobacteria by difference in time to growth detection in liquid media. Diagn Microbiol Infect Dis. 2013;75:73–6.
pubmed: 23114094
doi: 10.1016/j.diagmicrobio.2012.09.019
Lin C, Russell C, Soll B, Chow D, Bamrah S, Brostrom R, Kim W, Scott J, Bankowski MJ. Increasing prevalence of nontuberculous mycobacteria in respiratory specimens from US-Affiliated Pacific Island jurisdictions1. Emerg Infect Dis. 2018;24:485–91.
pubmed: 29460734
pmcid: 5823340
doi: 10.3201/eid2403.171301
Lopez-Luis BA, Sifuentes-Osornio J, Pérez-Gutiérrez MT, Chávez-Mazari B, Bobadilla-Del-Valle M, Ponce-de-León A. Nontuberculous mycobacterial infection in a tertiary care center in Mexico, 2001–2017. Braz J Infect Dis. 2020;24:213–20.
pubmed: 32428442
pmcid: 9392119
doi: 10.1016/j.bjid.2020.04.012
Hermansen TS, Ravn P, Svensson E, Lillebaek T. Nontuberculous mycobacteria in Denmark, incidence and clinical importance during the last quarter-century. Sci Rep. 2017;7:6696.
pubmed: 28751677
pmcid: 5532240
doi: 10.1038/s41598-017-06931-4
Prato BD, Altieri AM, Carlucci B, Mori PA, Parrella R, Stainer A, Giacomi FD, Pesci A, Faverio P, Gruppo di Studio AIPO “Patologie Infettive Respiratorie e Tubercolosi. Non-tuberculous mycobacterial pulmonary disease: an Italian national survey. Sarcoidosis Vasc Diffuse Lung Dis. 2018;35:21–5.
pubmed: 32476876
pmcid: 7170062
Dahl VN, Mølhave M, Fløe A, van Ingen J, Schön T, Lillebaek T, Andersen AB, Wejse C. Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review. Int J Infect Dis. 2022;125:120–31.
pubmed: 36244600
doi: 10.1016/j.ijid.2022.10.013
Donohue MJ, Wymer L. Increasing prevalence rate of nontuberculous mycobacteria infections in five states, 2008–2013. Ann Am Thorac Soc. 2016;13:2143–50.
pubmed: 27681202
doi: 10.1513/AnnalsATS.201605-353OC
Winthrop KL, Marras TK, Adjemian J, Zhang H, Wang P, Zhang Q. Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. managed care health plan, 2008–2015. Ann Am Thorac Soc. 2020;17:178–85.
pubmed: 31830805
pmcid: 6993793
doi: 10.1513/AnnalsATS.201804-236OC
Ringshausen FC, Apel R-M, Bange F-C, de Roux A, Pletz MW, Rademacher J, Suhling H, Wagner D, Welte T. Burden and trends of hospitalisations associated with pulmonary non-tuberculous mycobacterial infections in Germany, 2005–2011. BMC Infect Dis. 2013;13:231.
pubmed: 23692867
pmcid: 3667050
doi: 10.1186/1471-2334-13-231
Ringshausen FC, Wagner D, de Roux A, Diel R, Hohmann D, Hickstein L, Welte T, Rademacher J. Prevalence of nontuberculous mycobacterial pulmonary disease, Germany, 2009–2014. Emerg Infect Dis. 2016;22:1102–5.
pubmed: 27191473
pmcid: 4880102
doi: 10.3201/eid2206.151642
Dahl VN, Fløe A, Wejse C. Nontuberculous mycobacterial infections in a Danish region between 2011 and 2021: evaluation of trends in diagnostic codes. Infect Dis (Lond). 2023;55:439–43.
pubmed: 36995113
doi: 10.1080/23744235.2023.2194411
Kim J-Y, Kwak N, Yim J-J. The rise in prevalence and related costs of nontuberculous mycobacterial diseases in South Korea, 2010–2021. Open Forum Infect Dis. 2022;9:0fac649.
doi: 10.1093/ofid/ofac649
Cheng L-P, Chen S-H, Lou H, Gui X-W, Shen X-N, Cao J, Sha W, Sun Q. Factors associated with treatment outcome in patients with nontuberculous mycobacterial pulmonary disease: a large population-based retrospective cohort study in Shanghai. Trop Med Infect Dis. 2022;7:27.
pubmed: 35202222
pmcid: 8876156
doi: 10.3390/tropicalmed7020027
Hannah CE, Ford BA, Chung J, Ince D, Wanat KA. Characteristics of nontuberculous mycobacterial infections at a midwestern tertiary hospital: a retrospective study of 365 patients. Open Forum Infect Dis. 2020;7:ofaa173.
pubmed: 32587875
pmcid: 7305701
doi: 10.1093/ofid/ofaa173
Lee SW, Park Y, Kim S, Chung EK, Kang YA. Comorbidities of nontuberculous mycobacteria infection in Korean adults: results from the national health insurance service-national sample cohort (NHIS-NSC) database. BMC Pulm Med. 2022;22:283.
pubmed: 35870927
pmcid: 9308178
doi: 10.1186/s12890-022-02075-y
Prieto MD, Alam ME, Franciosi AN, Quon BS. Global burden of nontuberculous mycobacteria in the cystic fibrosis population: a systematic review and meta-analysis. ERJ Open Res. 2023;9:00336–2022.
pubmed: 36605902
pmcid: 9808535
doi: 10.1183/23120541.00336-2022
Lee EH, Chin B, Kim YK, Yoo JS, Choi Y-H, Kim S, Lee KH, Lee SJ, Kim J, Baek YJ, Kim JH, Ahn JY, Jeong SJ, Ku NS, Yeom J-S, Choi JY. Clinical characteristics of nontuberculous mycobacterial disease in people living with HIV/AIDS in South Korea: a multi-center, retrospective study. PLoS ONE. 2022;17: e0276484.
pubmed: 36355915
pmcid: 9648836
doi: 10.1371/journal.pone.0276484
Mejia-Chew C, Carver PL, Rutjanawech S, Camargo LFA, Fernandes R, Belga S, Daniels S-A, Müller NJ, Burkhard S, Theodoropoulos NM, Postma DF, van Duijn PJ, Fariñas MC, González-Rico C, Hand J, Lowe A, Bodro M, Vanino E, Cruz AF, Ramos A, Makek MJ, Mjahed RB, Manuel O, Kamar N, Calvo-Cano A, Carrasco LR, Muñoz P, Rodríguez S, Pérez-Recio S, Sabé N, Álvarez RR, Silva JT, Mularoni A, Vidal E, Alonso-Titos J, Del Rosal T, Classen AY, Goss CW, Agarwal M, López-Medrano F. Risk factors for nontuberculous mycobacteria infections in solid organ transplant recipients: a multinational case-control study. Clin Infect Dis. 2023;76:e995–1003.
pubmed: 35879465
doi: 10.1093/cid/ciac608
Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, Böttger EC, Brozek J, Griffith DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, Van Ingen J, Wagner D, Winthrop KL. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71:e1–36.
pubmed: 32628747
pmcid: 7768748
doi: 10.1093/cid/ciaa241
2023. Atypical Mycobacterial Diseases: Practice Essentials, Background, Pathophysiology.
Wi YM. Treatment of extrapulmonary nontuberculous mycobacterial diseases. Infect Chemother. 2019;51:245–55.
pubmed: 31583858
pmcid: 6779577
doi: 10.3947/ic.2019.51.3.245
Kasperbauer S, Huitt G. Management of extrapulmonary nontuberculous mycobacterial infections. Semin Respir Crit Care Med. 2013;34:143–50.
pubmed: 23460014
doi: 10.1055/s-0033-1333576
Stroffolini G, Gaviraghi A, Penna D, Piccioni P, Venuti F, Botto C, Trezzi M, Betti M, Sestini S, Erba PA, Lupia T, Di Perri G, Aliberti S, Calcagno A. 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with non-tuberculous mycobacterial infections. A case series on the use of nuclear medicine in NTM-PD. J Infect. 2023;S0163–4453:00142–51.
Wetzstein N, Kohl TA, Andres S, Schultze TG, Geil A, Kim E, Biciusca T, Hügel C, Hogardt M, Lehn A, Vehreschild MJGT, Wolf T, Niemann S, Maurer FP, Wichelhaus TA. Comparative analysis of phenotypic and genotypic antibiotic susceptibility patterns in Mycobacterium avium complex. Int J Infect Dis. 2020;93:320–8.
pubmed: 32147539
doi: 10.1016/j.ijid.2020.02.059
Faverio P, De Giacomi F, Bodini BD, Stainer A, Fumagalli A, Bini F, Luppi F, Aliberti S. Nontuberculous mycobacterial pulmonary disease: an integrated approach beyond antibiotics. ERJ Open Res. 2021;7:00574–2020.
pubmed: 34046491
pmcid: 8141831
doi: 10.1183/23120541.00574-2020
Lan C-C, Lai S-R, Chien J-Y. Nonpharmacological treatment for patients with nontuberculous mycobacterial lung disease. J Formos Med Assoc. 2020;119:S42–50.
pubmed: 32499207
doi: 10.1016/j.jfma.2020.05.013
Ali J. A multidisciplinary approach to the management of nontuberculous mycobacterial lung disease: a clinical perspective. Expert Rev Respir Med. 2021;15:663–73.
pubmed: 33593217
doi: 10.1080/17476348.2021.1887734
Faverio P, Stainer A, Bonaiti G, Zucchetti SC, Simonetta E, Lapadula G, Marruchella A, Gori A, Blasi F, Codecasa L, Pesci A, Chalmers JD, Loebinger MR, Aliberti S. Characterizing Non-tuberculous mycobacteria infection in bronchiectasis. Int J Mol Sci. 2016;17:1913.
pubmed: 27854334
pmcid: 5133910
doi: 10.3390/ijms17111913
Lipman M, Kunst H, Loebinger MR, Milburn HJ, King M. Non tuberculous mycobacteria pulmonary disease: patients and clinicians working together to improve the evidence base for care. Int J Infect Dis. 2021;113:S73–7.
pubmed: 33781905
doi: 10.1016/j.ijid.2021.03.064
Hwang H, Lee J-K, Heo EY, Kim DK, Lee HW. The factors associated with mortality and progressive disease of nontuberculous mycobacterial lung disease: a systematic review and meta-analysis. Sci Rep. 2023;13:7348.
pubmed: 37147519
pmcid: 10162985
doi: 10.1038/s41598-023-34576-z
Zhao Z, Hu H, Wang M, Li F, Tang H. Risk factors and mental health status in patients with non-tuberculous mycobacterial lung disease: a single center retrospective study. Front Public Health. 2022;10: 912651.
pubmed: 35979468
pmcid: 9376471
doi: 10.3389/fpubh.2022.912651
Im Y, Hwang NY, Kim K, Kim H, Kwon OJ, Jhun BW. Impact of time between diagnosis and treatment for nontuberculous mycobacterial pulmonary disease on culture conversion and all-cause mortality. Chest. 2022;161:1192–200.
pubmed: 34793759
doi: 10.1016/j.chest.2021.10.048
van Ingen J, Aksamit T, Andrejak C, Böttger EC, Cambau E, Daley CL, Griffith DE, Guglielmetti L, Holland SM, Huitt GA, Koh W-J, Lange C, Leitman P, Marras TK, Morimoto K, Olivier KN, Santin M, Stout JE, Thomson R, Tortoli E, Wallace RJ, Winthrop KL, Wagner D, for NTM-NET. Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. Eur Respir J. 2018;51:1800170.
pubmed: 29567726
pmcid: 6660914
doi: 10.1183/13993003.00170-2018
Nasiri MJ, Ebrahimi G, Arefzadeh S, Zamani S, Nikpor Z, Mirsaeidi M. Antibiotic therapy success rate in pulmonary Mycobacterium avium complex: a systematic review and meta-analysis. Expert Rev Anti Infect Ther. 2020;18:263–73.
pubmed: 31986933
doi: 10.1080/14787210.2020.1720650
Pasipanodya JG, Ogbonna D, Ferro BE, Magombedze G, Srivastava S, Deshpande D, Gumbo T. Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence. Antimicrob Agents Chemother. 2017;61:e01206-e1217.
pubmed: 28807911
pmcid: 5655093
doi: 10.1128/AAC.01206-17
Kwak N, Dalcolmo MP, Daley CL, Eather G, Gayoso R, Hasegawa N, Jhun BW, Koh W-J, Namkoong H, Park J, Thomson R, van Ingen J, Zweijpfenning SMH, Yim J-J. M ycobacterium abscessus pulmonary disease: individual patient data meta-analysis. Eur Respir J. 2019;54:1801991.
pubmed: 30880280
doi: 10.1183/13993003.01991-2018
Kim J-Y, Lee HW, Yim J-J, Kwak N. Outcomes of adjunctive surgery in patients with nontuberculous mycobacterial pulmonary disease: a systematic review and meta-analysis. Chest. 2023;163:763–77.
pubmed: 36208713
doi: 10.1016/j.chest.2022.09.037
Jhun BW, Moon SM, Jeon K, Kwon OJ, Yoo H, Carriere KC, Huh HJ, Lee NY, Shin SJ, Daley CL, Koh W-J. Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study. Eur Respir J. 2020;55:1900798.
pubmed: 31619468
doi: 10.1183/13993003.00798-2019
Kang H-R, Hwang EJ, Kim SA, Choi SM, Lee J, Lee C-H, Yim J-J, Kwak N. Clinical Implications of size of cavities in patients with nontuberculous mycobacterial pulmonary disease: a single-center cohort study. Open Forum Infect Dis. 2021;8:ofaB087.
pubmed: 33796599
pmcid: 7990513
doi: 10.1093/ofid/ofab087
Fukushima K, Kitada S, Komukai S, Kuge T, Matsuki T, Kagawa H, Tsujino K, Miki M, Miki K, Kida H. First line treatment selection modifies disease course and long-term clinical outcomes in Mycobacterium avium complex pulmonary disease. Sci Rep. 2021;11:1178.
pubmed: 33441977
pmcid: 7807086
doi: 10.1038/s41598-021-81025-w
Grosset J, Ji B. Prevention of the selection of clarithromycin-resistant Mycobacterium avium-intracellulare complex. Drugs. 1997;54:23–7.
pubmed: 9358197
doi: 10.2165/00003495-199700542-00006
Peloquin C. The role of therapeutic drug monitoring in mycobacterial infections. Microbiol Spectr. 2017. https://doi.org/10.1128/microbiolspec.TNMI7-0029-2016 .
doi: 10.1128/microbiolspec.TNMI7-0029-2016
pubmed: 28084209
Trentalange A, Borgogno E, Motta I, Antonucci M, Pirriatore V, Costa C, Rossi G, Barco A, De Nicolò A, Piccioni P, D’Avolio A, Bonora S, Di Perri G, Calcagno A. Rifampicin and isoniazid maximal concentrations are below efficacy-associated thresholds in the majority of patients: time to increase the doses? Int J Antimicrob Agents. 2021;57: 106297.
pubmed: 33539932
doi: 10.1016/j.ijantimicag.2021.106297
Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, Böttger EC, Brozek J, Griffith DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, van Ingen J, Wagner D, Winthrop KL. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020;56:2000535.
pubmed: 32636299
pmcid: 8375621
doi: 10.1183/13993003.00535-2020
Frost KJ, Hamilton RA, Hughes S, Jamieson C, Rafferty P, Troise O, Jenkins A. Systematic review of high-dose amikacin regimens for the treatment of gram-negative infections based on EUCAST dosing recommendations. Eur J Hosp Pharm. 2023;30:189–95.
pubmed: 36344247
doi: 10.1136/ejhpharm-2022-003421
Edson RS, Terrell CL. The aminoglycosides. Mayo Clin Proc. 1999;74:519–28.
pubmed: 10319086
doi: 10.1016/S0025-6196(11)65134-3
Bryan LE, Kowand SK, Van Den Elzen HM. Mechanism of aminoglycoside antibiotic resistance in anaerobic bacteria: clostridium perfringens and Bacteroides fragilis. Antimicrob Agents Chemother. 1979;15:7–13.
pubmed: 218500
pmcid: 352592
doi: 10.1128/AAC.15.1.7
Bryan LE, Van Den Elzen HM. Effects of membrane-energy mutations and cations on streptomycin and gentamicin accumulation by bacteria: a model for entry of streptomycin and gentamicin in susceptible and resistant bacteria. Antimicrob Agents Chemother. 1977;12:163–77.
pubmed: 143238
pmcid: 429880
doi: 10.1128/AAC.12.2.163
Nessar R, Reyrat JM, Murray A, Gicquel B. Genetic analysis of new 16S rRNA mutations conferring aminoglycoside resistance in Mycobacterium abscessus. J Antimicrob Chemother. 2011;66:1719–24.
pubmed: 21652621
pmcid: 3133489
doi: 10.1093/jac/dkr209
Lee S-Y, Kim H-Y, Kim B-J, Kim H, Seok S-H, Kim B-J, Kook Y-H. Effect of amikacin on cell wall glycopeptidolipid synthesis in Mycobacterium abscessus. J Microbiol. 2017;55:640–7.
pubmed: 28752292
doi: 10.1007/s12275-017-6503-7
Kolpen M, Jensen PØ, Qvist T, Kragh KN, Ravnholt C, Fritz BG, Johansen UR, Bjarnsholt T, Høiby N. Biofilms of Mycobacterium abscessus complex can be sensitized to antibiotics by disaggregation and oxygenation. Antimicrob Agents Chemother. 2020;64:e01212-e1219.
pubmed: 31740557
pmcid: 6985723
doi: 10.1128/AAC.01212-19
Prammananan T, Sander P, Brown BA, Frischkorn K, Onyi GO, Zhang Y, Böttger EC, Wallace RJ. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J Infect Dis. 1998;177:1573–81.
pubmed: 9607835
doi: 10.1086/515328
Brown-Elliott BA, Iakhiaeva E, Griffith DE, Woods GL, Stout JE, Wolfe CR, Turenne CY, Wallace RJ. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates. J Clin Microbiol. 2013;51:3389–94.
pubmed: 23946523
pmcid: 3811650
doi: 10.1128/JCM.01612-13
Rüger K, Hampel A, Billig S, Rücker N, Suerbaum S, Bange F-C. Characterization of rough and smooth morphotypes of Mycobacterium abscessus isolates from clinical specimens. J Clin Microbiol. 2014;52:244–50.
pubmed: 24197890
pmcid: 3911423
doi: 10.1128/JCM.01249-13
Raaijmakers J, Schildkraut JA, Hoefsloot W, van Ingen J. The role of amikacin in the treatment of nontuberculous mycobacterial disease. Expert Opin Pharmacother. 2021;22:1961–74.
pubmed: 34292097
doi: 10.1080/14656566.2021.1953472
Jhun BW, Yang B, Moon SM, Lee H, Park HY, Jeon K, Kwon OJ, Ahn J, Moon IJ, Shin SJ, Daley CL, Koh W-J. Amikacin inhalation as salvage therapy for refractory nontuberculous mycobacterial lung disease. Antimicrob Agents Chemother. 2018;62:e00011-18.
pubmed: 29661870
pmcid: 6021683
doi: 10.1128/AAC.00011-18
Vázquez-Laslop N, Mankin AS. How macrolide antibiotics work. Trends Biochem Sci. 2018;43:668–84.
pubmed: 30054232
pmcid: 6108949
doi: 10.1016/j.tibs.2018.06.011
Andini N, Nash KA. Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible. Antimicrob Agents Chemother. 2006;50:2560–2.
pubmed: 16801446
pmcid: 1489773
doi: 10.1128/AAC.00264-06
Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H, Niimi A, Suzuki K, Murayama T, Amitani R, Kuze F. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med. 1999;160:866–72.
pubmed: 10471610
doi: 10.1164/ajrccm.160.3.9811086
Kobashi Y, Yoshida K, Miyashita N, Niki Y, Oka M. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J Infect Chemother. 2006;12:195–202.
pubmed: 16944258
doi: 10.1007/s10156-006-0457-8
Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X, Girard W, Nelson K, Caccitolo J, Alvarez J, Shepherd S, Wilson R, Graviss EA, Wallace RJ. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006;174:928–34.
pubmed: 16858014
doi: 10.1164/rccm.200603-450OC
Moon SM, Park HY, Kim S-Y, Jhun BW, Lee H, Jeon K, Kim DH, Huh HJ, Ki C-S, Lee NY, Kim HK, Choi YS, Kim J, Lee S-H, Kim CK, Shin SJ, Daley CL, Koh W-J. Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant mycobacterium avium complex lung disease. Antimicrob Agents Chemother. 2016;60:6758–65.
pubmed: 27572413
pmcid: 5075083
doi: 10.1128/AAC.01240-16
Jeong B-H, Jeon K, Park HY, Kim S-Y, Lee KS, Huh HJ, Ki C-S, Lee NY, Shin SJ, Daley CL, Koh W-J. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2015;191:96–103.
pubmed: 25393520
doi: 10.1164/rccm.201408-1545OC
Shitrit D, Baum GL, Priess R, Lavy A, Shitrit AB-G, Raz M, Shlomi D, Daniele B, Kramer MR. Pulmonary Mycobacterium kansasii infection in Israel, 1999–2004: clinical features, drug susceptibility, and outcome. Chest. 2006;129:771–6.
pubmed: 16537880
doi: 10.1378/chest.129.3.771
Griffith DE, Brown-Elliott BA, Wallace RJ. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis. 2003;37:1178–82.
pubmed: 14557961
doi: 10.1086/378742
van Ingen J, Hoefsloot W, Mouton JW, Boeree MJ, van Soolingen D. Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance. Int J Antimicrob Agents. 2013;42:80–2.
pubmed: 23664674
doi: 10.1016/j.ijantimicag.2013.03.010
CaMoMy Trial: a prospective randomized clinical trial to compare six-months sputum conversion rate with a clarithromycin or moxifloxacin containing regimen in patients with a M. Xenopi pulmonary infection: intermediate analysis | B49. NON-TUBERCULOUS MYCOBACTERIAL DISEASE AND CASE REPORTS. https://www.atsjournals.org/doi/abs/ https://doi.org/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A3733 . Retrieved 20 July 2023.
Mougari F, Bouziane F, Crockett F, Nessar R, Chau F, Veziris N, Sapriel G, Raskine L, Cambau E. Selection of resistance to clarithromycin in Mycobacterium abscessus subspecies. Antimicrob Agents Chemother. 2017;61:e00943-e1016.
pubmed: 27799212
doi: 10.1128/AAC.00943-16
Jeon K, Kwon OJ, Lee NY, Kim B-J, Kook Y-H, Lee S-H, Park YK, Kim CK, Koh W-J. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med. 2009;180:896–902.
pubmed: 19661243
doi: 10.1164/rccm.200905-0704OC
Nash KA, Brown-Elliott BA, Wallace RJ. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother. 2009;53:1367–76.
pubmed: 19171799
pmcid: 2663066
doi: 10.1128/AAC.01275-08
Coolen N, Morand P, Martin C, Hubert D, Kanaan R, Chapron J, Honoré I, Dusser D, Audureau E, Veziris N, Burgel P-R. Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin. J Cyst Fibros. 2015;14:594–9.
pubmed: 25735458
doi: 10.1016/j.jcf.2015.02.006
Loewenstein D, van Balveren L, Lemson A, Hanemaaijer N, Hoefsloot W, van Ingen J. Monotherapy: key cause of macrolide-resistant Mycobacterium avium complex disease. Respir Med. 2023;217: 107366.
pubmed: 37481170
doi: 10.1016/j.rmed.2023.107366
Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, Biga S, Schlebusch S, Dash P, Bowler SD. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013;309:1260–7.
pubmed: 23532242
doi: 10.1001/jama.2013.2290
Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EHJ, Koppers RJH, van der Werf TS, Boersma WG. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309:1251–9.
pubmed: 23532241
doi: 10.1001/jama.2013.1937
Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RPG, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, Mc Neeley DF. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360:2397–405.
pubmed: 19494215
doi: 10.1056/NEJMoa0808427
Andries K, Verhasselt P, Guillemont J, Göhlmann HWH, Neefs J-M, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307:223–7.
pubmed: 15591164
doi: 10.1126/science.1106753
Guglielmetti L, Le Dû D, Jachym M, Henry B, Martin D, Caumes E, Veziris N, Métivier N, Robert J, MDR-TB Management Group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Cohort. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis. 2015;60:188–94.
pubmed: 25320286
doi: 10.1093/cid/ciu786
Laudone TW, Garner L, Kam CW, Esther CR, McKinzie CJ. Novel therapies for treatment of resistant and refractory nontuberculous mycobacterial infections in patients with cystic fibrosis. Pediatr Pulmonol. 2021;56:S55–68.
pubmed: 32609433
doi: 10.1002/ppul.24939
AIFA. Mefoxin RCP.
Czaja CA, Levin A, Moridani M, Krank JL, Curran-Everett D, Anderson PL. Cefoxitin continuous infusion for lung infection caused by the Mycobacterium abscessus group. Antimicrob Agents Chemother. 2014;58:3570–1.
pubmed: 24733469
pmcid: 4068483
doi: 10.1128/AAC.02763-14
He G, Wu L, Zheng Q, Jiang X. Antimicrobial susceptibility and minimum inhibitory concentration distribution of common clinically relevant non-tuberculous mycobacterial isolates from the respiratory tract. Ann Med. 2022;54:2500–10.
pubmed: 36120867
pmcid: 9518250
doi: 10.1080/07853890.2022.2121984
Lee M-C, Sun P-L, Wu T-L, Wang L-H, Yang C-H, Chung W-H, Kuo A-J, Liu T-P, Lu J-J, Chiu C-H, Lai H-C, Chen N-Y, Yang J-H, Wu T-S. Antimicrobial resistance in Mycobacterium abscessus complex isolated from patients with skin and soft tissue infections at a tertiary teaching hospital in Taiwan. J Antimicrob Chemother. 2017;72:2782–6.
pubmed: 29091186
doi: 10.1093/jac/dkx212
Tang SS, Lye DC, Jureen R, Sng L-H, Hsu LY. Rapidly growing mycobacteria in Singapore, 2006–2011. Clin Microbiol Infect. 2015;21:236–41.
pubmed: 25658536
doi: 10.1016/j.cmi.2014.10.018
Durão V, Silva A, Macedo R, Durão P, Santos-Silva A, Duarte R. Portuguese in vitro antibiotic susceptibilities favor current nontuberculous mycobacteria treatment guidelines. Pulmonology. 2019;25:162–7.
pubmed: 30309821
doi: 10.1016/j.pulmoe.2018.09.001
Wang J, Huang J, Peng S, Li L, Zhong K, Chen T. A clinical case and a review of Mycobacterium fortuitum infections direct diagnosis approach and treatment in a patient with leg fractures. J Infect Dev Ctries. 2022;16:1650–4.
pubmed: 36332221
doi: 10.3855/jidc.16635
Wong KP, Tang ZH, Tan GM. Mycobacterium fortuitum and Mycobacterium abscessus infections in the foot and ankle in two immunocompetent patients. Biomedicine (Taipei). 2020;10:52–6.
pubmed: 33854936
doi: 10.37796/2211-8039.1021
Giovannenze F, Stifano V, Scoppettuolo G, Damiano F, Pallavicini F, Delogu G, Palucci I, Rapisarda A, Sturdà C, Pompucci A. Incidental intraoperative diagnosis of Mycobacterium abscessus meningeal infection: a case report and review of the literature. Infection. 2018;46:591–7.
pubmed: 29687315
doi: 10.1007/s15010-018-1141-5
Mushtaq RF, Bappa A, Ahmad M, AlShaebi F. Skin, subcutaneous tissue, and allograft infection with Mycobacterium fortuitum in a renal transplant recipient. Saudi J Kidney Dis Transpl. 2014;25:1248–50.
pubmed: 25394443
doi: 10.4103/1319-2442.144260
Kang N, Jeon K, Kim H, Kwon OJ, Huh HJ, Lee NY, Daley CL, Koh W-J, Jhun BW. Outcomes of inhaled amikacin-containing multidrug regimens for mycobacterium abscessus pulmonary disease. Chest. 2021;160:436–45.
pubmed: 33621600
doi: 10.1016/j.chest.2021.02.025
Li H, Tong L, Wang J, Liang Q, Zhang Y, Chu N, Chen X, Duan H. An Intensified regimen containing linezolid could improve treatment response in Mycobacterium abscessus lung disease. Biomed Res Int. 2019;2019:8631563.
pubmed: 31828137
pmcid: 6885786
doi: 10.1155/2019/8631563
Thompson PW, Williams JK. Mandibular osteomyelitis and cervical lymphadenitis due to Mycobacterium abscessus: surgical management of a pediatric cohort with a shared epidemiologic exposure. J Craniofac Surg. 2017;28:1960–5.
pubmed: 28938329
doi: 10.1097/SCS.0000000000004003
Pulcini C, Mohrs S, Beovic B, Gyssens I, Theuretzbacher U, Cars O, ESCMID Study Group for Antibiotic Policies (ESGAP), ReAct Working Group on Old Antibiotics. Forgotten antibiotics: a follow-up inventory study in Europe, the USA, Canada and Australia. Int J Antimicrob Agents. 2017;49:98–101.
pubmed: 27887966
doi: 10.1016/j.ijantimicag.2016.09.029
Maymone MBC, Venkatesh S, Laughter M, Abdat R, Hugh J, Dacso MM, Rao PN, Stryjewska BM, Dunnick CA, Dellavalle RP. Leprosy: treatment and management of complications. J Am Acad Dermatol. 2020;83:17–30.
pubmed: 32244016
doi: 10.1016/j.jaad.2019.10.138
Mirzayev F, Viney K, Linh NN, Gonzalez-Angulo L, Gegia M, Jaramillo E, Zignol M, Kasaeva T. World health organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. Eur Respir J. 2021;57:2003300.
pubmed: 33243847
pmcid: 8176349
doi: 10.1183/13993003.03300-2020
Cholo MC, Mothiba MT, Fourie B, Anderson R. Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline. J Antimicrob Chemother. 2017;72:338–53.
pubmed: 27798208
doi: 10.1093/jac/dkw426
Faouzi M, Starkus J, Penner R. State-dependent blocking mechanism of K
pubmed: 26276903
pmcid: 4687807
doi: 10.1111/bph.13283
Ammerman NC, Swanson RV, Tapley A, Moodley C, Ngcobo B, Adamson J, Dorasamy A, Moodley S, Mgaga Z, Bester LA, Singh SD, Almeida DV, Grosset JH. Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo. J Antimicrob Chemother. 2017;72:455–61.
pubmed: 27798204
doi: 10.1093/jac/dkw417
Lee JM, Park J, Choi S, Jhun BW, Kim S-Y, Jo K-W, Hong JJ, Kim L-H, Shin SJ. A clofazimine-containing regimen confers improved treatment outcomes in macrophages and in a murine model of chronic progressive pulmonary infection caused by the Mycobacterium avium complex. Front Microbiol. 2021;11: 626216.
pubmed: 33519787
pmcid: 7841306
doi: 10.3389/fmicb.2020.626216
Lanoix J-P, Joseph C, Peltier F, Castelain S, Andréjak C. Synergistic activity of clofazimine and clarithromycin in an aerosol mouse model of Mycobacterium avium Infection. Antimicrob Agents Chemother. 2020;64:e02349-e2419.
pubmed: 32071046
pmcid: 7179583
doi: 10.1128/AAC.02349-19
Kim B-G, Kim H, Kwon OJ, Huh HJ, Lee NY, Baek S-Y, Sohn I, Jhun BW. Outcomes of inhaled amikacin and clofazimine-containing regimens for treatment of refractory Mycobacterium avium complex pulmonary disease. JCM. 2020;9:2968.
pubmed: 32937940
pmcid: 7565500
doi: 10.3390/jcm9092968
Zweijpfenning SMH, Kops SEP, Boeree MJ, Kuipers S, Van Ingen J, Hoefsloot W, Magis-Escurra C. Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study. ERJ Open Res. 2021;7:00466–2021.
pubmed: 34820449
pmcid: 8607114
doi: 10.1183/23120541.00466-2021
Asami T, Aono A, Chikamatsu K, Igarashi Y, Morishige Y, Murase Y, Yamada H, Takaki A, Mitarai S. Efficacy estimation of a combination of triple antimicrobial agents against clinical isolates of Mycobacterium abscessus subsp. abscessus in vitro. JAC-Antimicrob Resist. 2021;3: dlab004.
pubmed: 34223082
pmcid: 8210157
doi: 10.1093/jacamr/dlab004
Kunkel M, Doyle-Eisele M, Kuehl P, Rotermund K, Hittinger M, Ufer S, Reed M, Grant M, Hofmann T. Clofazimine inhalation suspension demonstrates promising toxicokinetics in canines for treating pulmonary nontuberculous mycobacteria infection. Antimicrob Agents Chemother. 2023;67:e01144-e1222.
pubmed: 36648233
pmcid: 9933692
doi: 10.1128/aac.01144-22
Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann J-L, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, Van Ingen J, Wallace RJ, Winthrop KL, Marshall BC, Haworth CS. US cystic fibrosis foundation and European cystic fibrosis society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2016;71:i1–22.
pubmed: 26666259
doi: 10.1136/thoraxjnl-2015-207360
Hasse B, Hannan MM, Keller PM, Maurer FP, Sommerstein R, Mertz D, Wagner D, Fernández-Hidalgo N, Nomura J, Manfrin V, Bettex D, Hernandez Conte A, Durante-Mangoni E, Tang TH-C, Stuart RL, Lundgren J, Gordon S, Jarashow MC, Schreiber PW, Niemann S, Kohl TA, Daley CL, Stewardson AJ, Whitener CJ, Perkins K, Plachouras D, Lamagni T, Chand M, Freiberger T, Zweifel S, Sander P, Schulthess B, Scriven JE, Sax H, van Ingen J, Mestres CA, Diekema D, Brown-Elliott BA, Wallace RJ, Baddour LM, Miro JM, Hoen B, M. chimaera ISCVID Investigators and, ISCVID Executive Committee, Athan E, Bayer A, Barsic B, Corey GR, Chu VH, Durack DT, Fortes CQ, Fowler V, Hoen B, Krachmer AW, Durante-Magnoni E, Miro JM, Wilson WR, Infectious Diseases Specialists, Hospital Epidemiologists, Microbiologists and Molecular Typing Specialists, Cardiac Surgeons/ Perfusionists/ Cardiologists, Ophthalmology, Anaesthesiologists, Public Health. 2020. International Society of Cardiovascular Infectious Diseases Guidelines for the Diagnosis, Treatment and Prevention of Disseminated Mycobacterium chimaera Infection Following Cardiac Surgery with Cardiopulmonary Bypass. J Hosp Infect 104:214–235
Nasiri MJ, Calcagno T, Hosseini SS, Hematian A, Nojookambari NY, Karimi-Yazdi M, Mirsaeidi M. Role of clofazimine in treatment of Mycobacterium avium complex. Front Med. 2021;8:638306.
doi: 10.3389/fmed.2021.638306
Martiniano SL, Wagner BD, Levin A, Nick JA, Sagel SD, Daley CL. Safety and effectiveness of clofazimine for primary and refractory nontuberculous mycobacterial infection. Chest. 2017;152:800–9.
pubmed: 28483608
doi: 10.1016/j.chest.2017.04.175
Yang B, Jhun BW, Moon SM, Lee H, Park HY, Jeon K, Kim DH, Kim S-Y, Shin SJ, Daley CL, Koh W-J. Clofazimine-containing regimen for the treatment of mycobacterium abscessus lung disease. Antimicrob Agents Chemother. 2017;61:e02052-e2116.
pubmed: 28348153
pmcid: 5444135
doi: 10.1128/AAC.02052-16
Chan WY-K, Ho P-L, To KK-W, Lam AY-L, Ho KW-Y, Lau T-W, So NL-W, Ha S-Y. A child with acute myeloid leukemia complicated by calcaneal osteomyelitis due to Mycobacterium abscessus infection after induction chemotherapy successfully salvaged with bedaquiline and clofazimine. Int J Infect Dis. 2021;103:9–12.
pubmed: 33160065
doi: 10.1016/j.ijid.2020.10.102
Pinapala A, Koh LJ, Ng K-H, Tambyah PA, Yap H-K. Clofazimine in Mycobacterium abscessus peritonitis: a pediatric case report. Perit Dial Int. 2021;41:104–9.
pubmed: 32148178
doi: 10.1177/0896860820909702
Adler-Shohet FC, Singh J, Nieves D, Ashouri N, Tran MT, Flores MC, Arrieta A. Safety and tolerability of clofazimine in a cohort of children with odontogenic Mycobacterium abscessus infection. J Pediatric Infect Dis Soc. 2020;9:483–5.
pubmed: 31310313
doi: 10.1093/jpids/piz049
Hajikhani B, Nasiri MJ, Hosseini SS, Khalili F, Karimi-Yazdi M, Hematian A, Nojookambari NY, Goudarzi M, Dadashi M, Mirsaeidi M. Clofazimine susceptibility testing of Mycobacterium avium complex and Mycobacterium abscessus: a meta-analysis study. J Glob Antimicrob Resist. 2021;26:188–93.
pubmed: 34153525
doi: 10.1016/j.jgar.2021.06.002
Kwak N, Whang J, Yang JS, Kim TS, Kim SA, Yim J-J. Minimal inhibitory concentration of clofazimine among clinical isolates of nontuberculous mycobacteria and its impact on treatment outcome. Chest. 2021;159:517–23.
pubmed: 32712225
doi: 10.1016/j.chest.2020.07.040
Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, Brust JCM, Campbell JR, Chang VWL, Falzon D, Guglielmetti L, Isaakidis P, Kempker RR, Kipiani M, Kuksa L, Lange C, Laniado-Laborín R, Nahid P, Rodrigues D, Singla R, Udwadia ZF, Menzies D, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode S, Brust J, Campbell J, Chang V, Falzon D, Guglielmetti L, Isaakidis P, Kempker R, Kipiani M, Kuksa L, Lan Z, Lange C, Laniado-Laborín R, Nahid P, Rodrigues D, Singla R, Udwadia Z, Menzies D. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2020;8:383–94.
pubmed: 32192585
pmcid: 7384398
doi: 10.1016/S2213-2600(20)30047-3
Wallace RJ, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother. 2002;46:3164–7.
pubmed: 12234839
doi: 10.1128/AAC.46.10.3164-3167.2002
Park S, Kim S, Park EM, Kim H, Kwon OJ, Chang CL, Lew WJ, Park YK, Koh W-J. In vitro antimicrobial susceptibility of Mycobacterium abscessus in Korea. J Korean Med Sci. 2008;23:49–52.
pubmed: 18303198
pmcid: 2526484
doi: 10.3346/jkms.2008.23.1.49
Cantillon D, Goff A, Taylor S, Salehi E, Fidler K, Stoneham S, Waddell SJ. Searching for new therapeutic options for the uncommon pathogen Mycobacterium chimaera: an open drug discovery approach. Lancet Microbe. 2022;3:e382–91.
pubmed: 35544099
pmcid: 9042791
doi: 10.1016/S2666-5247(21)00326-8
Zhang L, Zhao Y, Gao Y, Wu L, Gao R, Zhang Q, Wang Y, Wu C, Wu F, Gurcha SS, Veerapen N, Batt SM, Zhao W, Qin L, Yang X, Wang M, Zhu Y, Zhang B, Bi L, Zhang X, Yang H, Guddat LW, Xu W, Wang Q, Li J, Besra GS, Rao Z. Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol. Science. 2020;368:1211–9.
pubmed: 32327601
doi: 10.1126/science.aba9102
Goude R, Amin AG, Chatterjee D, Parish T. The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2009;53:4138–46.
pubmed: 19596878
pmcid: 2764220
doi: 10.1128/AAC.00162-09
Lim S-A. Ethambutol-associated optic neuropathy. Ann Acad Med Singap. 2006;35:274–8.
pubmed: 16710500
doi: 10.47102/annals-acadmedsg.V35N4p274
Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74:839–54.
pubmed: 24846578
doi: 10.1007/s40265-014-0222-8
Bobrowitz ID. Ethambutol in pregnancy. Chest. 1974;66:20–4.
pubmed: 4843599
doi: 10.1378/chest.66.1.20
Matsumoto Y, Murata M, Takayama K, Yamasaki S, Hiramine S, Toyoda K, Kibe Y, Nishida R, Kimura S, Sonoda H, Shiose A, Shimono N. A case of mediastinal abscess and infected aortic aneurysm caused by dissemination of Mycobacterium abscessus subsp. massiliense pulmonary disease. J Infect Chemother. 2023;29:82–6.
pubmed: 36162647
doi: 10.1016/j.jiac.2022.09.017
Schoutrop ELM, Brouwer MAE, Jenniskens JCA, Ferro BE, Mouton JW, Aarnoutse RE, van Ingen J. The stability of antimycobacterial drugs in media used for drug susceptibility testing. Diagn Microbiol Infect Dis. 2018;92:305–8.
pubmed: 30025972
doi: 10.1016/j.diagmicrobio.2018.06.015
Lavollay M, Dubée V, Heym B, Herrmann J-L, Gaillard J-L, Gutmann L, Arthur M, Mainardi J-L. In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex. Clin Microbiol Infect. 2014;20:O297-300.
pubmed: 24112243
doi: 10.1111/1469-0691.12405
Harada T, Akiyama Y, Kurashima A, Nagai H, Tsuyuguchi K, Fujii T, Yano S, Shigeto E, Kuraoka T, Kajiki A, Kobashi Y, Kokubu F, Sato A, Yoshida S, Iwamoto T, Saito H. Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases. J Clin Microbiol. 2012;50:3556–61.
pubmed: 22915613
pmcid: 3486228
doi: 10.1128/JCM.01175-12
Jayasingam SD, Zin T, Ngeow YF. Antibiotic resistance in Mycobacterium Abscessus and Mycobacterium Fortuitum isolates from Malaysian patients. Int J Mycobacteriol. 2017;6:387–90.
pubmed: 29171453
doi: 10.4103/ijmy.ijmy_152_17
Takei S, Ihara H, Togo S, Nakamura A, Fujimoto Y, Watanabe J, Kurokawa K, Shibayama K, Sumiyoshi I, Ochi Y, Iwai M, Okabe T, Chonan M, Misawa S, Ohsaka A, Takahashi K. The synergetic effect of Imipenem-clarithromycin combination in the Mycobacteroides abscessus complex. BMC Microbiol. 2020;20:316.
pubmed: 33076820
pmcid: 7574464
doi: 10.1186/s12866-020-02000-5
Brown-Elliott BA, Killingley J, Vasireddy S, Bridge L, Wallace RJ. In vitro comparison of ertapenem, meropenem, and imipenem against isolates of rapidly growing mycobacteria and nocardia by use of broth microdilution and Etest. J Clin Microbiol. 2016;54:1586–92.
pubmed: 27053677
pmcid: 4879266
doi: 10.1128/JCM.00298-16
Yang S-C, Hsueh P-R, Lai H-C, Teng L-J, Huang L-M, Chen J-M, Wang S-K, Shie D-C, Ho S-W, Luh K-T. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. Antimicrob Agents Chemother. 2003;47:1958–62.
pubmed: 12760874
pmcid: 155839
doi: 10.1128/AAC.47.6.1958-1962.2003
Pang H, Jiang Y, Wan K. Drug susceptibility of 33 reference strains of slowly growing mycobacteria to 19 antimicrobial agents. Biomed Res Int. 2017;2017:1584658.
pubmed: 28512635
pmcid: 5415667
doi: 10.1155/2017/1584658
Roest S, Bax HI, Verkaik NJ, Brugts JJ, Constantinescu AA, de Bakker CC, Birim O, Caliskan K, Manintveld OC. Mycobacterium chelonae, an “atypical” cause of an LVAD driveline infection. Int J Infect Dis. 2020;92:127–9.
pubmed: 31926352
doi: 10.1016/j.ijid.2020.01.002
Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, Leitch A, Loebinger MR, Milburn HJ, Nightingale M, Ormerod P, Shingadia D, Smith D, Whitehead N, Wilson R, Floto RA. British thoracic society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72:11–164.
doi: 10.1136/thoraxjnl-2017-210929
van Wijk F, Waterval J, van Aerde K, Henriet SSV, Meijer FJA, Borra LC, Aarnoutse RE, van Ingen J. Successful systemic and topical treatment of Mycobacterium abscessus otomastoiditis. Antimicrob Agents Chemother. 2019;64:e01203-e1219.
pubmed: 31611360
pmcid: 7187624
Heifets L. Susceptibility testing of Mycobacterium avium complex isolates. Antimicrob Agents Chemother. 1996;40:1759–67.
pubmed: 8843278
pmcid: 163414
doi: 10.1128/AAC.40.8.1759
Research Committee of the British Thoracic Society. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax. 2001;56:167–72.
doi: 10.1136/thorax.56.3.167
Ahn CH, Lowell JR, Ahn SS, Ahn SI, Hurst GA. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am Rev Respir Dis. 1983;128:1048–50.
pubmed: 6650978
Sauret J, Hernández-Flix S, Castro E, Hernández L, Ausina V, Coll P. Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months’ chemotherapy. Tuber Lung Dis. 1995;76:104–8.
pubmed: 7780090
doi: 10.1016/0962-8479(95)90550-2
Foti C, Piperno A, Scala A, Giuffrè O. Oxazolidinone antibiotics: chemical, biological and analytical aspects. Molecules. 2021;26:4280.
pubmed: 34299555
pmcid: 8305375
doi: 10.3390/molecules26144280
Senol G, Bicmen C, Gunduz A, Dereli S, Erbaycu A. Evaluation of antimicrobial susceptibilities of non-tuberculous mycobacteria against linezolid and tigecycline. Indian J Med Microbiol. 2022;40:446–8.
pubmed: 35450734
doi: 10.1016/j.ijmmb.2022.03.012
Kim S-Y, Jhun BW, Moon SM, Jeon K, Kwon OJ, Huh HJ, Lee NY, Shin SJ, Daley CL, Koh W-J. Genetic mutations in linezolid-resistant Mycobacterium avium complex and Mycobacterium abscessus clinical isolates. Diagn Microbiol Infect Dis. 2019;94:38–40.
pubmed: 30581010
doi: 10.1016/j.diagmicrobio.2018.10.022
Zhang H, Hua W, Lin S, Zhang Y, Chen X, Wang S, Chen J, Zhang W. In vitro susceptibility of nontuberculous mycobacteria to tedizolid. Infect Drug Resist. 2022;15:4845–52.
pubmed: 36045871
pmcid: 9422992
doi: 10.2147/IDR.S362583
Ruth MM, Koeken VACM, Pennings LJ, Svensson EM, Wertheim HFL, Hoefsloot W, van Ingen J. Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease? J Antimicrob Chemother. 2020;75:609–17.
pubmed: 31886864
doi: 10.1093/jac/dkz511
Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, Brust JCM, Campbell JR, Chang VWL, Falzon D, Guglielmetti L, Isaakidis P, Kempker RR, Kipiani M, Kuksa L, Lange C, Laniado-Laborín R, Nahid P, Rodrigues D, Singla R, Udwadia ZF, Menzies D, Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment 2017. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2020;8:383–94.
pubmed: 32192585
pmcid: 7384398
doi: 10.1016/S2213-2600(20)30047-3
Winthrop KL, Ku JH, Marras TK, Griffith DE, Daley CL, Olivier KN, Aksamit TR, Varley CD, Mackey K, Prevots DR. The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease. Eur Respir J. 2015;45:1177–9.
pubmed: 25614169
pmcid: 6660918
doi: 10.1183/09031936.00169114
Poon YK, La Hoz RM, Hynan LS, Sanders J, Monogue ML. Tedizolid vs linezolid for the treatment of nontuberculous mycobacteria infections in solid organ transplant recipients. Open Forum Infect Dis. 2021;8: ofab093.
pubmed: 33884276
pmcid: 8047851
doi: 10.1093/ofid/ofab093
Janik JP, Bang RH, Palmer CH. Case reports: successful treatment of Mycobacterium marinum infection with minocycline after complication of disease by delayed diagnosis and systemic steroids. J Drugs Dermatol. 2005;4:621–4.
pubmed: 16167421
Rhomberg PR, Jones RN. In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum. Diagn Microbiol Infect Dis. 2002;42:145–7.
pubmed: 11858912
doi: 10.1016/S0732-8893(01)00332-7
Cummins DL, Delacerda D, Tausk FA. Mycobacterium marinum with different responses to second-generation tetracyclines. Int J Dermatol. 2005;44:518–20.
pubmed: 15941446
doi: 10.1111/j.1365-4632.2005.02204.x
Roussel G, Igual J. Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d’Etude et de traitement des Infections à Mycobactéries. Int J Tuberc Lung Dis. 1998;2:462–70.
pubmed: 9626603
Ruth MM, Sangen JJN, Pennings LJ, Schildkraut JA, Hoefsloot W, Magis-Escurra C, Wertheim HFL, van Ingen J. Minocycline has no clear role in the treatment of mycobacterium abscessus disease. Antimicrob Agents Chemother. 2018;62:e01208-e1218.
pubmed: 30104268
pmcid: 6153809
doi: 10.1128/AAC.01208-18
Sano C, Tatano Y, Shimizu T, Yamabe S, Sato K, Tomioka H. Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium. Int J Antimicrob Agents. 2011;37:296–301.
pubmed: 21353489
doi: 10.1016/j.ijantimicag.2010.12.014
Koh W-J, Hong G, Kim S-Y, Jeong B-H, Park HY, Jeon K, Kwon OJ, Lee S-H, Kim CK, Shin SJ. Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. Antimicrob Agents Chemother. 2013;57:2281–5.
pubmed: 23478956
pmcid: 3632919
doi: 10.1128/AAC.02281-12
Brown Elliott BA, Wallace RJ. Comparison of in vitro susceptibility of delafloxacin with ciprofloxacin, moxifloxacin, and other comparator antimicrobials against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother. 2021;65: e0007921.
pubmed: 33846136
doi: 10.1128/AAC.00079-21
Park YE, Chong YP, Lee HJ, Shim TS, Jo K-W. Clinical outcome with standard regimen plus clofazimine or moxifloxacin in cavitary Mycobacterium avium complex pulmonary disease. Antimicrob Agents Chemother. 2022;66: e0052822.
pubmed: 36326247
doi: 10.1128/aac.00528-22
Lee JH, Park YE, Chong YP, Shim TS, Jo K-W. Efficacy of fluoroquinolones as substitutes for ethambutol or rifampin in the treatment of Mycobacterium avium complex pulmonary disease according to radiologic types. Antimicrob Agents Chemother. 2022;66: e0152221.
pubmed: 34930036
doi: 10.1128/aac.01522-21
Koh W-J, Jeong B-H, Kim S-Y, Jeon K, Park KU, Jhun BW, Lee H, Park HY, Kim DH, Huh HJ, Ki C-S, Lee NY, Kim HK, Choi YS, Kim J, Lee S-H, Kim CK, Shin SJ, Daley CL, Kim H, Kwon OJ. Mycobacterial characteristics and treatment outcomes in Mycobacterium abscessus lung disease. Clin Infect Dis. 2017;64:309–16.
pubmed: 28011608
doi: 10.1093/cid/ciw724
Andréjak C, Almeida DV, Tyagi S, Converse PJ, Ammerman NC, Grosset JH. Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy. J Antimicrob Chemother. 2013;68:659–65.
pubmed: 23129730
doi: 10.1093/jac/dks421
Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev. 2010;23:14–34.
pubmed: 20065324
pmcid: 2806656
doi: 10.1128/CMR.00034-09
Sirgel FA, Warren RM, Böttger EC, Klopper M, Victor TC, van Helden PD. The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks. PLoS ONE. 2013;8: e59414.
pubmed: 23527189
pmcid: 3602005
doi: 10.1371/journal.pone.0059414
Rothstein DM. Rifamycins, alone and in combination. Cold Spring Harb Perspect Med. 2016;6: a027011.
pubmed: 27270559
pmcid: 4930915
doi: 10.1101/cshperspect.a027011
Boorgula GD, Jakkula LUMR, Gumbo T, Jung B, Srivastava S. Comparison of rifamycins for efficacy against Mycobacterium avium Complex and resistance emergence in the hollow fiber model system. Front Pharmacol. 2021;12: 645264.
pubmed: 33935740
pmcid: 8085489
doi: 10.3389/fphar.2021.645264
Chapagain M, Gumbo T, Heysell SK, Srivastava S. Comparison of a novel regimen of rifapentine, tedizolid, and minocycline with standard regimens for treatment of pulmonary Mycobacterium kansasii. Antimicrob Agents Chemother. 2020;64:e00810-e820.
pubmed: 32690646
pmcid: 7508568
doi: 10.1128/AAC.00810-20
Kim DH, Kim S-Y, Huh HJ, Lee NY, Koh W-J, Jhun BW. In vitro activity of rifamycin derivatives against nontuberculous mycobacteria, including macrolide-/amikacin-resistant clinical isolates. Antimicrob Agents Chemother. 2023;65:e02611-e2620.
pubmed: 33685889
Ganapathy US, Dartois V, Dick T. Repositioning rifamycins for Mycobacterium abscessus lung disease. Expert Opin Drug Discov. 2019;14:867–78.
pubmed: 31195849
pmcid: 6663560
doi: 10.1080/17460441.2019.1629414
Gordin FM, Sullam PM, Shafran SD, Cohn DL, Wynne B, Paxton L, Perry K, Horsburgh CR. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin Infect Dis. 1999;28:1080–5.
pubmed: 10452638
doi: 10.1086/514748
Zuur MA, Pasipanodya JG, van Soolingen D, van der Werf TS, Gumbo T, Alffenaar J-WC. Intermediate susceptibility dose-dependent breakpoints for high-dose rifampin, isoniazid, and pyrazinamide treatment in multidrug-resistant tuberculosis programs. Clin Infect Dis. 2018;67:1743–9.
pubmed: 29697766
Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M, PanACEA consortium. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017;17:39–49.
pubmed: 28100438
pmcid: 5159618
doi: 10.1016/S1473-3099(16)30274-2
Milstein M, Lecca L, Peloquin C, Mitchison D, Seung K, Pagano M, Coleman D, Osso E, Coit J, Vargas Vasquez DE, Sanchez Garavito E, Calderon R, Contreras C, Davies G, Mitnick CD. Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial. BMC Infect Dis. 2016;16:453.
pubmed: 27567500
pmcid: 5002098
doi: 10.1186/s12879-016-1790-x
Griffith DE, Brown BA, Girard WM, Wallace RJ. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis. 1995;21:594–8.
pubmed: 8527549
doi: 10.1093/clinids/21.3.594
Cheng A, Tsai Y-T, Chang S-Y, Sun H-Y, Wu U-I, Sheng W-H, Chen Y-C, Chang S-C. In vitro synergism of rifabutin with clarithromycin, imipenem, and tigecycline against the mycobacterium abscessus complex. Antimicrob Agents Chemother. 2019;63:e02234-e2318.
pubmed: 30670428
pmcid: 6437537
doi: 10.1128/AAC.02234-18
Aziz DB, Low JL, Wu M-L, Gengenbacher M, Teo JWP, Dartois V, Dick T. Rifabutin is active against Mycobacterium abscessus complex. Antimicrob Agents Chemother. 2017;61:e00155-e217.
pubmed: 28396540
pmcid: 5444174
doi: 10.1128/AAC.00155-17
Magis-Escurra C, Alffenaar JW, Hoefnagels I, Dekhuijzen PNR, Boeree MJ, van Ingen J, Aarnoutse RE. Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections. Int J Antimicrob Agents. 2013;42:256–61.
pubmed: 23837923
doi: 10.1016/j.ijantimicag.2013.05.007
Schildkraut JA, Raaijmakers J, Aarnoutse R, Hoefsloot W, Wertheim HFL, van Ingen J. The role of rifampicin within the treatment of Mycobacterium avium pulmonary disease. Antimicrob Agents Chemother. 2023;67: e0087423.
pubmed: 37877693
doi: 10.1128/aac.00874-23
Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother. 1999;43:738–44.
pubmed: 10103174
pmcid: 89200
doi: 10.1128/AAC.43.4.738
Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis. 2005;41:S303-314.
pubmed: 16080069
doi: 10.1086/431672
García-Agudo L, García-Martos P, Jesús I, Rodríguez-Iglesias M. Assessment of in vitro susceptibility to antimicrobials of rapidly growing mycobacteria by E-test. Rev Med Chil. 2009;137:912–7.
pubmed: 19802419
Peres E, Khaled Y, Krijanovski OI, Mineishi S, Levine JE, Kaul DR, Riddell J. Mycobacterium chelonae necrotizing pneumonia after allogeneic hematopoietic stem cell transplant: report of clinical response to treatment with tigecycline. Transpl Infect Dis. 2009;11:57–63.
pubmed: 18983415
doi: 10.1111/j.1399-3062.2008.00351.x
Shen Y, Wang X, Jin J, Wu J, Zhang X, Chen J, Zhang W. In vitro susceptibility of Mycobacterium abscessus and Mycobacterium fortuitum isolates to 30 antibiotics. Biomed Res Int. 2018;2018:4902941.
pubmed: 30687747
pmcid: 6330815
doi: 10.1155/2018/4902941
Wallace RJ, Dukart G, Brown-Elliott BA, Griffith DE, Scerpella EG, Marshall B. Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections. J Antimicrob Chemother. 2014;69:1945–53.
pubmed: 24633206
pmcid: 4054987
doi: 10.1093/jac/dku062
Lange C, Böttger EC, Cambau E, Griffith DE, Guglielmetti L, van Ingen J, Knight SL, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, Wagner D, Winthrop K, Daley CL. Expert panel group for management recommendations in non-tuberculous mycobacterial pulmonary diseases. 2022. Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. Lancet Infect Dis. 2022;22:e178–90.
pubmed: 35090639
doi: 10.1016/S1473-3099(21)00586-7
Fernandez-Pittol M, Batista-Arnau S, Román A, San Nicolás L, Oliver L, González-Moreno O, Martínez JA, Amaro-Rodríguez R, Soler N, Gené A, González-Cuevas A, Tudó G, Gonzalez-Martin J. Differences in drug-susceptibility patterns between Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium chimaera clinical isolates: prospective 85-year analysis by three laboratories. Antibiotics (Basel). 2022;12:64.
pubmed: 36671265
doi: 10.3390/antibiotics12010064
Hunkins J-J, de-Moura V-C-N, Eddy J-J, Daley C-L, Khare R. In vitro susceptibility patterns for rapidly growing nontuberculous mycobacteria in the United States. Diagn Microbiol Infect Dis. 2023;105:115882.
pubmed: 36610383
doi: 10.1016/j.diagmicrobio.2022.115882
Rodríguez-Cerdeira C, Hernández-Castro R, Sánchez-Cárdenas CD, Arenas R, Meza-Robles A, Toussaint-Caire S, Atoche-Diéguez C, Martínez-Herrera E. Atypical mycobacteriosis due to Mycobacterium abscessus subsp. massiliense: our experince. Pathogens. 2022;11:1399.
pubmed: 36558733
pmcid: 9782088
doi: 10.3390/pathogens11121399
Zhang T, Du J, Dong L, Wang F, Zhao L, Jia J, Wang C, Cheng M, Yu X, Huang H. In vitro antimicrobial activities of tigecycline, eravacycline, omadacycline, and sarecycline against rapidly growing mycobacteria. Microbiol Spectr. 2023;11: e0323822.
pubmed: 36475850
doi: 10.1128/spectrum.03238-22
Kaushik A, Ammerman NC, Martins O, Parrish NM, Nuermberger EL. In vitro activity of new tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of Mycobacterium abscessus. Antimicrob Agents Chemother. 2019;63:e00470-e519.
pubmed: 30962331
pmcid: 6535573
doi: 10.1128/AAC.00470-19
Chew KL, Octavia S, Go J, Ng S, Tang YE, Soh P, Yong J, Jureen R, Lin RTP, Yeoh SF, Teo J. In vitro susceptibility of Mycobacterium abscessus complex and feasibility of standardizing treatment regimens. J Antimicrob Chemother. 2021;76:973–8.
pubmed: 33338230
doi: 10.1093/jac/dkaa520
Li A, Tan Z, He S, Chu H. In vitro susceptibility testing of tetracycline-class antibiotics against slowly growing non-tuberculous mycobacteria. Clin Exp Pharmacol Physiol. 2023;50:604–9.
pubmed: 37086075
doi: 10.1111/1440-1681.13777
Brown-Elliott BA, Wallace RJ. In vitro susceptibility testing of eravacycline against nontuberculous mycobacteria. Antimicrob Agents Chemother. 2022;66: e0068922.
pubmed: 35943269
doi: 10.1128/aac.00689-22
Brown-Elliott BA, Wallace RJ. In vitro susceptibility testing of omadacycline against nontuberculous mycobacteria. Antimicrob Agents Chemother. 2021;65:e01947-e2020.
pubmed: 33288634
pmcid: 8092516
doi: 10.1128/AAC.01947-20
Shoen C, Benaroch D, Sklaney M, Cynamon M. In vitro activities of omadacycline against rapidly growing mycobacteria. Antimicrob Agents Chemother. 2019;63:e02522-e2618.
pubmed: 30858221
pmcid: 6496053
doi: 10.1128/AAC.02522-18
Pearson JC, Dionne B, Richterman A, Vidal SJ, Weiss Z, Velásquez GE, Marty FM, Sax PE, Yawetz S. Omadacycline for the treatment of Mycobacterium abscessus disease: a case series. Open Forum Infect Dis. 2020;7:ofaa415.
pubmed: 33094118
pmcid: 7566545
doi: 10.1093/ofid/ofaa415
Nicklas DA, Maggioncalda EC, Story-Roller E, Eichelman B, Tabor C, Serio AW, Keepers TR, Chitra S, Lamichhane G. Potency of omadacycline against Mycobacteroides abscessus clinical isolates in vitro and in a mouse model of pulmonary infection. Antimicrob Agents Chemother. 2022;66: e0170421.
pubmed: 34662184
doi: 10.1128/AAC.01704-21
Singh S, Gumbo T, Boorgula GD, Shankar P, Heysell SK, Srivastava S. Omadacycline pharmacokinetics/pharmacodynamics in the hollow fiber system model and potential combination regimen for short course treatment of Mycobacterium kansasii pulmonary disease. Antimicrob Agents Chemother. 2022;66: e0068722.
pubmed: 35976006
doi: 10.1128/aac.00687-22
Chapagain M, Pasipanodya JG, Athale S, Bernal C, Trammell R, Howe D, Gumbo T. Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses. J Antimicrob Chemother. 2022;77:1694–705.
pubmed: 35257162
pmcid: 9155607
doi: 10.1093/jac/dkac068
Wang G, Tang J, Feng J, Dong W, Huo X, Lu H, Wang C, Lu W, Wang X, Chen H, Tan C. Activity of Oritavancin and its synergy with other antibiotics against Mycobacterium abscessus infection in vitro and in vivo. Int J Mol Sci. 2021;22:6346.
pubmed: 34198513
pmcid: 8231898
doi: 10.3390/ijms22126346
Sun Q, Liao X, Wang C, Jiang G, Yang J, Zhao J, Huang H, Wang G, Li H. In vitro activity of fidaxomicin against nontuberculosis mycobacteria. J Med Microbiol. 2022. https://doi.org/10.1099/jmm.0.001549 .
doi: 10.1099/jmm.0.001549
pubmed: 35737512
Kim DH, Jhun BW, Moon SM, Kim S-Y, Jeon K, Kwon OJ, Huh HJ, Lee NY, Shin SJ, Daley CL, Koh W-J. In vitro activity of bedaquiline and delamanid against nontuberculous mycobacteria, including macrolide-resistant clinical isolates. Antimicrob Agents Chemother. 2019;63:e00665-e719.
pubmed: 31182533
pmcid: 6658790
doi: 10.1128/AAC.00665-19
Yu X, Gao X, Li C, Luo J, Wen S, Zhang T, Ma Y, Dong L, Wang F, Huang H. In vitro activities of bedaquiline and delamanid against nontuberculous mycobacteria isolated in Beijing, China. Antimicrob Agents Chemother. 2019;63:e00031-e119.
pubmed: 31138571
pmcid: 6658755
doi: 10.1128/AAC.00031-19
Zheng L, Qi X, Zhang W, Wang H, Fu L, Wang B, Chen X, Chen X, Lu Y. Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum in BALB/c mice models. Front Cell Infect Microbiol. 2023;13:1115530.
pubmed: 37077530
pmcid: 10106926
doi: 10.3389/fcimb.2023.1115530
Zheng H, Wang Y, He W, Li F, Xia H, Zhao B, Wang S, Shen C, Zhao Y. In vitro activity of pretomanid against nontuberculous mycobacteria. Antimicrob Agents Chemother. 2022;66: e0181021.
pubmed: 34723628
doi: 10.1128/AAC.01810-21
Soroka D, Dubée V, Soulier-Escrihuela O, Cuinet G, Hugonnet J-E, Gutmann L, Mainardi J-L, Arthur M. Characterization of broad-spectrum Mycobacterium abscessus class A β-lactamase. J Antimicrob Chemother. 2014;69:691–6.
pubmed: 24132992
doi: 10.1093/jac/dkt410
Dubée V, Bernut A, Cortes M, Lesne T, Dorchene D, Lefebvre A-L, Hugonnet J-E, Gutmann L, Mainardi J-L, Herrmann J-L, Gaillard J-L, Kremer L, Arthur M. β-lactamase inhibition by avibactam in Mycobacterium abscessus. J Antimicrob Chemother. 2015;70:1051–8.
pubmed: 25525201
doi: 10.1093/jac/dku510
Le Run E, Atze H, Arthur M, Mainardi J-L. Impact of relebactam-mediated inhibition of Mycobacterium abscessus blamab β-lactamase on the in vitro and intracellular efficacy of imipenem. J Antimicrob Chemother. 2020;75:379–83.
pubmed: 31637424
Misawa K, Nishimura T, Kashimura S, Enoki Y, Taguchi K, Uno S, Uwamino Y, Matsumoto K, Hasegawa N. In vitro effects of diazabicyclooctane β-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex. Int J Antimicrob Agents. 2022;60: 106669.
pubmed: 36064079
doi: 10.1016/j.ijantimicag.2022.106669
Lopeman RC, Harrison J, Rathbone DL, Desai M, Lambert PA, Cox JAG. Effect of amoxicillin in combination with imipenem-relebactam against Mycobacterium abscessus. Sci Rep. 2020;10:928.
pubmed: 31988293
pmcid: 6985242
doi: 10.1038/s41598-020-57844-8
Kaushik A, Ammerman NC, Lee J, Martins O, Kreiswirth BN, Lamichhane G, Parrish NM, Nuermberger EL. In vitro activity of the new β-lactamase inhibitors relebactam and vaborbactam in combination with β-lactams against Mycobacterium abscessus complex clinical isolates. Antimicrob Agents Chemother. 2019;63:e02623-e2718.
pubmed: 30642943
pmcid: 6395916
Kaushik A, Ammerman NC, Parrish NM, Nuermberger EL. New β-lactamase inhibitors nacubactam and zidebactam improve the in vitro activity of β-lactam antibiotics against mycobacterium abscessus complex clinical isolates. Antimicrob Agents Chemother. 2019;63:e00733-e819.
pubmed: 31209013
pmcid: 6709484
Dedrick RM, Guerrero-Bustamante CA, Garlena RA, Russell DA, Ford K, Harris K, Gilmour KC, Soothill J, Jacobs-Sera D, Schooley RT, Hatfull GF, Spencer H. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med. 2019;25:730–3.
pubmed: 31068712
pmcid: 6557439
doi: 10.1038/s41591-019-0437-z
Rm D, Be S, Ra G, Da R, Hg A, V M, Am D, Ca G-B, Km Z, L A, Ch G, D J-S, Gf H. Mycobacterium abscessus strain morphotype determines phage susceptibility, the repertoire of therapeutically useful phages, and phage resistance. MBio. 2021;12:e03431-e3520.
Nick JA, Dedrick RM, Gray AL, Vladar EK, Smith BE, Freeman KG, Malcolm KC, Epperson LE, Hasan NA, Hendrix J, Callahan K, Walton K, Vestal B, Wheeler E, Rysavy NM, Poch K, Caceres S, Lovell VK, Hisert KB, de Moura VC, Chatterjee D, De P, Weakly N, Martiniano SL, Lynch DA, Daley CL, Strong M, Jia F, Hatfull GF, Davidson RM. Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell. 2022;185:1860-1874.e12.
pubmed: 35568033
pmcid: 9840467
doi: 10.1016/j.cell.2022.04.024
Dedrick RM, Smith BE, Cristinziano M, Freeman KG, Jacobs-Sera D, Belessis Y, Whitney Brown A, Cohen KA, Davidson RM, van Duin D, Gainey A, Garcia CB, Robert George CR, Haidar G, Ip W, Iredell J, Khatami A, Little JS, Malmivaara K, McMullan BJ, Michalik DE, Moscatelli A, Nick JA, Tupayachi Ortiz MG, Polenakovik HM, Robinson PD, Skurnik M, Solomon DA, Soothill J, Spencer H, Wark P, Worth A, Schooley RT, Benson CA, Hatfull GF. Phage therapy of mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease. Clin Infect Dis. 2023;76:103–12.
pubmed: 35676823
doi: 10.1093/cid/ciac453
Rs W, A O, A S, A W. Host-directed immunotherapy of viral and bacterial infections: past, present and future. Nat Rev Immunol. 2023;23:121–33.
doi: 10.1038/s41577-022-00734-z
G K, A S, Thm O, Mc H. Host-directed therapy to combat mycobacterial infections. Immunol Rev. 2021;301:62–83.
doi: 10.1111/imr.12951
Napier RJ, Rafi W, Cheruvu M, Powell KR, Zaunbrecher MA, Bornmann W, Salgame P, Shinnick TM, Kalman D. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe. 2011;10:475–85.
pubmed: 22100163
pmcid: 3222875
doi: 10.1016/j.chom.2011.09.010
Nannini EC, Keating M, Binstock P, Samonis G, Kontoyiannis DP. Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine. J Infect. 2002;44:201–3.
pubmed: 12099753
doi: 10.1053/jinf.2002.0970
de Silva TI, Cope A, Goepel J, Greig JM. The use of adjuvant granulocyte-macrophage colony-stimulating factor in HIV-related disseminated atypical mycobacterial infection. J Infect. 2007;54:e207-210.
pubmed: 17197031
doi: 10.1016/j.jinf.2006.11.005
Kedzierska K, Mak J, Mijch A, Cooke I, Rainbird M, Roberts S, Paukovics G, Jolley D, Lopez A, Crowe SM. Granulocyte-macrophage colony-stimulating factor augments phagocytosis of Mycobacterium avium complex by human immunodeficiency virus type 1-infected monocytes/macrophages in vitro and in vivo. J Infect Dis. 2000;181:390–4.
pubmed: 10608795
doi: 10.1086/315191
Bermudez LE, Stevens P, Kolonoski P, Wu M, Young LS. Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor. J Immunol. 1989;143:2996–3000.
pubmed: 2553816
doi: 10.4049/jimmunol.143.9.2996
Trojan T, Collins R, Khan DA. Safety and efficacy of treatment using interleukin-2 in a patient with idiopathic CD4(+) lymphopenia and Mycobacterium avium-intracellulare. Clin Exp Immunol. 2009;156:440–5.
doi: 10.1111/j.1365-2249.2009.03910.x
Vázquez N, Greenwell-Wild T, Rekka S, Orenstein JM, Wahl SM. Mycobacterium avium-induced SOCS contributes to resistance to IFN-gamma-mediated mycobactericidal activity in human macrophages. J Leukoc Biol. 2006;80:1136–44.
doi: 10.1189/jlb.0306206
Palucci I, Salustri A, De Maio F, Pereyra Boza MDC, Paglione F, Sali M, Occhigrossi L, D'Eletto M, Rossin F, Goletti D, Sanguinetti M, Piacentini M, Delogu G. Cysteamine/Cystamine Exert Anti-Mycobacterium abscessus Activity Alone or in Combination with Amikacin. Int J Mol Sci. 2023;24:1203.
pubmed: 36674717
pmcid: 9866335
doi: 10.3390/ijms24021203
Alonzi T, Aiello A, Petrone L, Najafi Fard S, D’Eletto M, Falasca L, Nardacci R, Rossin F, Delogu G, Castilletti C, Capobianchi MR, Ippolito G, Piacentini M, Goletti D. Cysteamine with in vitro antiviral activity and immunomodulatory effects has the potential to be a repurposing drug candidate for COVID-19 therapy. Cells. 2021;11:52.
pubmed: 35011614
pmcid: 8750154
doi: 10.3390/cells11010052
Ricotta EE, Prevots DR, Olivier KN. CFTR modulator use and risk of nontuberculous mycobacteria positivity in cystic fibrosis, 2011–2018. ERJ Open Res. 2022;8:00724–2021.
pubmed: 35415188
pmcid: 8995538
doi: 10.1183/23120541.00724-2021